Skip to main content
. Author manuscript; available in PMC: 2010 May 1.
Published in final edited form as: Cancer Res. 2009 Apr 14;69(9):3731–3735. doi: 10.1158/0008-5472.CAN-09-0096

Fig. 2.

Fig. 2

Validation of metabolites that were distinguished as biomarkers for metabolic changes following silibinin treatment (see Figure 1B). Panels A–C plot individual concentrations ([µmol/g] prostate tissue, n=4 for each data set) for each metabolite or metabolite ratios as calculated from 1H-NMR spectra of hydrophilic and lipophilic fractions (Table 1).